menu
    • menu
    [{"orgOrder":0,"company":"Biodesix","sponsor":"Biodesix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Erlotinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Biodesix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biodesix \/ Biodesix","highestDevelopmentStatusID":"10","companyTruncated":"Biodesix \/ Biodesix"},{"orgOrder":0,"company":"Biodesix","sponsor":"AVEO Pharmaceuticals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Ficlatuzumab","moa":"Hepatocyte growth factor","graph1":"Oncology","graph2":"Phase II","graph3":"Biodesix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biodesix \/ Biodesix","highestDevelopmentStatusID":"8","companyTruncated":"Biodesix \/ Biodesix"},{"orgOrder":0,"company":"Biodesix","sponsor":"AVEO Pharmaceuticals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ficlatuzumab","moa":"Hepatocyte growth factor","graph1":"Oncology","graph2":"Phase II","graph3":"Biodesix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biodesix \/ Biodesix","highestDevelopmentStatusID":"8","companyTruncated":"Biodesix \/ Biodesix"},{"orgOrder":0,"company":"Biodesix","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"Cetuximab","moa":"||Hepatocyte growth factor","graph1":"Oncology","graph2":"Phase II","graph3":"Biodesix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biodesix \/ Biodesix","highestDevelopmentStatusID":"8","companyTruncated":"Biodesix \/ Biodesix"}]

    Find Clinical Drug Pipeline Developments & Deals by Biodesix

    Menu

    Biodesix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biodesix

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Biodesix

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ficlatuzumab,Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Aveo Oncology

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AVEO Oncology Regains Full Global Rights to Ficlatuzumab

                            Details : Under the terms of the deal, Biodesix will continue to fund 50% of the ongoing HNSCC Phase 2 trial of ficlatuzumab, and will be entitled to a low double digit royalty on any future product sales as well as 25% of future licensing revenue, subject to cert...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 08, 2020

                            Lead Product(s) : Ficlatuzumab,Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Aveo Oncology

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biodesix

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Biodesix

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ficlatuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : AVEO Pharmaceuticals, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemi...

                            Details : Ficlatuzumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 24, 2019

                            Lead Product(s) : Ficlatuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : AVEO Pharmaceuticals, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biodesix

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Biodesix

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ficlatuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : AVEO Pharmaceuticals, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreat...

                            Details : Ficlatuzumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 17, 2014

                            Lead Product(s) : Ficlatuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : AVEO Pharmaceuticals, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biodesix

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Biodesix

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Erlotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : ETOP IBCSG Partners Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using Veri...

                            Details : Erlotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 30, 2012

                            Lead Product(s) : Erlotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : ETOP IBCSG Partners Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth